Tag Archives: UK

Introduction Goals of care for patients with HF are to provide symptom relief, improve prognosis and quality of life, and prevent hospitalisations. Patients with HF are often complex, and multi-disciplinary input is recommended so that patients receive evidence-based treatments and maximise their quality of life.1 In the UK, the National Health Service (NHS) encompasses both hospital and community HF services, which work together to keep people living with HF supported and well-managed.2 Community HF teams provide specialist care for patients with HF, and community services are structured around outpatient appointments in healthcare settings

Introduction Heart failure (HF) is a clinical syndrome due to a structural or functional abnormality of the heart that results in elevated intracardiac pressure or inadequate cardiac output at rest or during exercise.1 It affects around 900,000 people in the UK and poses a significant burden on the National Health Service (NHS), accounting for one million bed days per year.2 HF reduces life-expectancy with a one-year survival rate of 75.9% post-diagnosis and a 10-year survival of 24.5%.3 Patients living with HF also suffer from disability and reduced quality of life.4 With an ageing population, greater survival from myocardial infarctions (MI

British Heart Foundation The biggest independent funder of cardiovascular research in the UK, The British Heart Foundation plays a leading role in the fight against diseases of the heart and circulation by support of vital, pioneering research into their causes, prevention, diagnosis and treatment through research grants. It funds around £100 million of heart research every year. https://www.bhf.org.uk/research/information-for-researchers British Cardiovascular Society/BJCA The British Cardiovascular Society is a registered charity that aims to support and represents those working in cardiovascular care and research, by providing access to t

‘The NHS has indicated that research is a clear priority in improving healthcare for patients’ Figure 1. The case trial timeline, intervals are in days A summary of the article’s key learning points Obtaining approval for conducting clinical research can be an extremely lengthy endeavor (see figure below). The process makes a four-month term in research almost useless, unless you begin the application process at least nine months in advance of a trial’s expected start date. You will need more than a year if you are applying for external funding. Work closely with the relevant organisations, particularly the R&D department of

Importance of UK collaboration with the EU The partnerships between the UK and other EU Member States significantly increase the impact and influence of the EU’s science and research activity. When collaborating with the UK, the share of EU co-authored publications in the top 10% of highly cited publications in medical and health research is higher.2 The UK is also a top five collaboration partner for each of the other 27 Member States,3 and contributed almost 20% of the total research work carried out within EU health programmes between 2007–2016.2 European collaboration is particularly important in some fields – stratified medicine a

The Institute of Cardiovascular Medicine and Science (ICMS) is a world-class body set up to improve outcomes in cardiovascular medicine drawing on the combined clinical expertise of its founding partners: Royal Brompton and Hare eld NHS Foundation Trust (RB&HFT) and Liverpool Heart and Chest Hospital NHS Foundation Trust (LHCH). Founded in 2011 as a joint venture, it was formed as a company limited by guarantee and registered at Companies’ House. Initial investment by each Trust of £50,000 was followed up by further investment in 2015 of £50,000 by each Trust. It is supported by its academic partner, Imperial College London. The I

The innovative and trustworthy use of routinely collected healthcare data has enabled a UK company, NorthWest Ehealth, experts in the use of this technology, to become the only organisation in the world to have evaluated the safety and effectiveness of a pre-license medicine in a real-world setting. Its technology can support the whole clinical trial lifecycle and enable more effective feasibility, economic modelling, recruitment, real-time safety monitoring and data analytics. ‘The use of electronic healthcare records for clinical research is helping change the clinical trial landscape’ The EHR and future of clinical trials The use of e

The NIHR represents the most integrated health research system in the world and is the research arm of the National Health Service (NHS). Its national network enables access to experts and trained staff in all therapeutic specialties across the country and opens up collaboration possibilities between groups with similar research interests. The NHS: an incredible research resource the largest publicly funded health service in the world looks after one million people every 36 hours all inclusive, free to access, it provides a representative population, with the NHS number a unique identifier for patients so they can be followed through the

‘The UK is a dynamic place to conduct research’ This handbook seeks to introduce the research landscape in the UK. There are many different avenues that research can take. These include research in academic institutions, healthcare organisations, charities and industry. There is much collaboration and partnership between different sectors, including sharing of big data. This environment, with its excellent academic, clinical and commercial interaction, makes the UK a dynamic place to conduct research. We describe some UK research models in this handbook based, in part, on presentations made at a meeting, sponsored by Novartis, entitled �

No content available